CAR T-cell therapy treats cancer. But can it also cause it?

FDA has opened an investigation into CAR T-cell therapies, a type of cancer treatment that involves genetically modifying immune cells, after the agency received several reports of patients developing lymphoma after receiving the treatment.

Top drivers of change in the oncology market

What is CAR T-cell therapy?

In CAR T-cell therapy, a type of white blood cell called T cells are removed from a patient’s blood before being genetically modified to make proteins called chimeric antigen receptors (CAR). These receptors allow T cells to target and destroy cancer cells. The genetically modified T cells are then infused back into a...